Regardless, even though 38 displays reduced MDCK permeability it is still comparable to, or better than, other known CNS active drugs. As 38 emerged as our lead molecule from this series we performed further cheminformatic absorption, metabolism, distribution and excretion (ADME) analysis using pkCSM the 38 as a potential inhibitor cytochrome P450s (CYP) 1A2 and 3A4 and substrate of CYP3A4 and CYP2D6. Metabolism and inhibition of CYPs can adversely impact the metabolic profiles of the lead molecule and other drugs taken in combination. Thus, the effect of small molecules on CYPs should be assessed to de-risk the scaffold for lead optimization. To this end, we evaluated 38 for inhibition at five CYPs that contribute to metabolism of over 50% of marketed drugs. The molecule was dosed at a single concentration of 10 µM and evaluated for percent inhibition.